Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | PAK1 | Q13153 | 1/20 | 1.00 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | ERN1 | O75460 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29354769 | 1.00 | USP2 (1.00) | USP2PAK1PTPN22POLBHSD17B10 | |
| SCHEMBL11181173 | 0.91 | USP2 (0.84) | USP2PAK1PTPN22POLBHSD17B10 | |
| SCHEMBL20812358 | 0.89 | USP2 (0.79) | USP2PAK1PTPN22POLBHSD17B10 | |
| SCHEMBL753620 | 0.86 | USP2 (0.76) | USP2PAK1PTPN22POLBHSD17B10 | |
| SCHEMBL11660677 | 0.83 | USP2 (0.70) | USP2PAK1PTPN22POLBHSD17B10 | |
| SCHEMBL6274433 | 0.83 | USP2 (0.70) | USP2PAK1PTPN22POLBHSD17B10 | |
| SCHEMBL222299 | 0.77 | USP2 (0.63) | USP2PAK1PTPN22POLBHSD17B10 | |
| SCHEMBL7192775 | 0.77 | USP2 (0.61) | USP2PAK1PTPN22POLBHSD17B10 | |
| SCHEMBL14773895 | 0.75 | USP2 (0.59) | USP2PAK1PTPN22POLBHSD17B10 | |
| SCHEMBL31587632 | 0.74 | USP2 (0.58) | USP2PAK1PTPN22POLBHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114957592-B | Polyurethane elastomer for self-healing in blood environment and preparation method and application thereof | 中国科学院宁波材料技术与工程研究所 | 2024-07-26 | — | — | CN | claimed |
| CN-118063832-A | Non-stick type yoghurt packaging composite material and preparation method thereof | 安徽紫金新材料科技股份有限公司 | 2024-05-24 | — | — | CN | claimed |
| CN-115584120-B | Preparation method of polyurethane elastomer composite material with negative poisson ratio property | 北京化工大学 | 2024-03-01 | — | — | CN | claimed |
| CN-116023613-A | Polyurethane elastomer for self-repairing blood environment and preparation method and application thereof | 中国科学院宁波材料技术与工程研究所 | 2023-04-28 | — | — | CN | claimed |
| CN-115584120-A | Preparation method of polyurethane elastomer composite material with negative Poisson ratio property | 北京化工大学 | 2023-01-10 | — | — | CN | claimed |
| CN-114957592-A | Polyurethane elastomer capable of self-healing blood environment and preparation method and application thereof | 中国科学院宁波材料技术与工程研究所 | 2022-08-30 | — | — | CN | claimed |
| WO-2016161033-A1 | METHODS FOR MAKING OLIGOMERIC ACIDS AND ROSIN OIL FROM CRUDE TALL OIL | GEORGIA-PACIFIC CHEMICALS LLC (US) | 2016-10-06 | — | — | WO | claimed |
| US-20150359815-A1 | PAK1 INHIBITION FOR TREATMENT OF ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2015-12-17 | — | — | US | claimed |
| WO-2014150790-A1 | PAK1 INHIBITION FOR TREATMENT OF ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2014-09-25 | — | — | WO | claimed |
| JP-57179154-A | — | — | None | — | — | JP | disclosed |
| US-20250041294-A1 | Synergistic compositions for use in the treatment of cancer | SARTAR THERAPEUTICS OY (FI) | 2025-02-06 | — | — | US | disclosed |
| WO-2024261302-A1 | NLRP3 INHIBITORS, PAK1/2 INHIBITORS AND/OR CASPASE 1 INHIBITORS FOR USE IN THE TREATMENT OF RAC2 MONOGENIC DISORDERS | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-12-26 | — | — | WO | disclosed |
| EP-4444314-A1 | SYNERGISTIC COMPOSITIONS FOR USE IN THE TREATMENT OF CANCER | Sartar Therapeutics Oy (FI) | 2024-10-16 | — | — | EP | disclosed |
| CN-114957592-B | Polyurethane elastomer for self-healing in blood environment and preparation method and application thereof | 中国科学院宁波材料技术与工程研究所 | 2024-07-26 | — | — | CN | disclosed |
| US-8771682-B2 | Methods and compositions for reducing interleukin-4 or interleukin-13 signaling | Technische Universtität Dresden (DE) | 2014-07-08 | — | — | US | disclosed |
| US-8771682-B2 | Methods and compositions for reducing interleukin-4 or interleukin-13 signaling | Technische Universtität Dresden (DE) | 2014-07-08 | — | — | US | disclosed |
| US-20130084275-A1 | Methods and Compositions for Reducing Interleukin-4 or Interleukin-13 Signaling | TECHNISCHE UNIVERSITAT DRESDEN (DE) | 2013-04-04 | — | — | US | disclosed |
| US-20130084275-A1 | Methods and Compositions for Reducing Interleukin-4 or Interleukin-13 Signaling | TECHNISCHE UNIVERSITAT DRESDEN (DE) | 2013-04-04 | — | — | US | disclosed |
| US-20080097062-A1 | Method of Producing Disproportionated Rosin | ALBEMARLE CORPORATION (US) | 2008-04-24 | — | — | US | disclosed |
| JP-S57179154-A | PREPARATION OF 2,2'-DIHYDROXY-1,1'-DINAPHTHYL DISULFIDE | MITSUI TOATSU CHEM INC | 1982-11-04 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130084275-A1 | Methods and Compositions for Reducing Interleukin-4 or Interleukin-13 Signaling | IL4, IL2RA, STAT6 | USP2 3157/4885PAK1 60/4885PTPN22 635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.